Abstract
Identifying more sensitive biomarker tests for Alzheimer’s disease (AD) is an unmet medical need. It is key in the global efforts to validate disease-modifying AD therapeutics and identify appropriate recipients in clinical trials once more therapies are approved. Fluid biomarkers, especially plasma-based biomarkers, become the most attractive ones as they are non-invasive, relatively economical, and easy to obtain. Emerging blood biomarkers, including amyloid ß monomers, oligomers, tau/p-tau, neurofilament light chain, and inflammatory factors, are gathering tremendous research interest.
However, there are also challenges in developing blood biomarkers for neurological disease with specificity, precision, and reproducibility. First, biologically, there could be a tiny amount of proteins of the central nervous system entering into the peripheral bloodstream. Second, biochemically, the enriched and complex matrix of human blood strongly interferes with the detection system we use for protein identification and quantification. Third, technically, it is critical to establish a system with high reliability that is also capable of high throughput. Our expert speakers will discuss strategies in developing an ultrasensitive immunoassay to precisely measure oligomeric amyloid ß in human plasma samples.
During the webinar, the viewers will:
- Obtain insights into blood-based biomarkers used in neurological diseases such as Alzheimer’s disease.
- Discover the challenges and opportunities behind creating blood-based biomarker immunoassays.
For Research Use Only. Not For Use In Diagnostic Procedures.
Speakers
Lei Liu, MD, PhD
Harvard Medical School
Assistant Professor of Neurology
Lei Liu, MD, PhD, studied the neurochemistry of Alzheimer’s disease (AD) at the Shiga University of Medical Science (Otsu, Japan) and completed his Ph.D. thesis in the lab of Dr. Masaki Nishimura. Following his research interest in dementia, he joined the lab of Dr. Dennis Selkoe at Harvard Medical School/Brigham and Women’s Hospital in late 2016, where he currently works as an Assistant Professor of Neurology at Harvard Medical School. He has published many significant peer-reviewed research articles on the enzymology involved in AD pathogenesis in prestigious journals, such as Journal of Cell Biology, Nature Communications, Alzheimer’s & Dementia, Neuron, and Journal of Biological Chemistry. In addition to basic molecular biology research, he is also an expert in antibody biology and immunoassay development.
Anitaben Tailor, Ph.D.
Merck
Biology Technical Marketing
Anitaben Tailor brings over 10 years of immunoassay platform experience in the biopharmaceutical industry. After her post-doctoral fellowship, she held faculty positions at Johns Hopkins and NIH; then joined the industry in a global role with Merck's Life Science division. More recently, she focuses on the technical marketing of the Immunoassay portfolio within Pharma and CROs.
Protein biology
- Protein quantitation
期间:1h 7min
语言:English
场次 1:往期 December 12, 2021
如要继续阅读，请登录或创建帐户。
暂无帐户？